Cool Excimer Laser-Assisted Angioplasty vs. Percutaneous Transluminal Angioplasty for Infrapopliteal Arterial Occlusion: A Meta-Analysis and Systematic Review

Mi Zhou, Lixing Qi and Yongquan Gu*

Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China

Background: Percutaneous transluminal angioplasty (PTA) has been the conventional therapy to infrapopliteal arterial occlusion. Lately, cool excimer laser-assisted angioplasty has been proposed to be the alternate methods. We performed a systematic review and meta-analysis of prospective and retrospective cohort studies and randomized controlled trials to assess the effect of cool excimer laser-assisted angioplasty vs. tibial balloon angioplasty in patients with infrapopliteal arterial occlusion.

Methods and Results: We systematically searched PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) (all up to April, 2021). All prospective and retrospective cohort studies and randomized controlled trials comparing clinical outcomes between cool excimer laser-assisted angioplasty and tibial balloon angioplasty were included. The main endpoints were amputation-free survival (AFS), primary patency (6 months and 12 months) and free from target lesion revascularization (TLR) (3 years). Secondary outcomes included the major amputation (1 year), dissection, embolization and bailout stent. We chose the effect model according to studies’ heterogeneity. A total of 122 articles were found. According to inclusion criteria, 6 papers were finally selected for the detailed evaluation. Of the 6 papers, 4 were prospective cohort studies, and 2 were retrospective studies. Compared with PTA, CELA significantly increased the rate of patency (6 months: MD 13.01, 95% CI 3.12-22.90, \( P < 0.05 \); 12 months: MD 11.88 95% CI 8.38-15.37, \( P < 0.05 \)) and the rate freedom from TLR (36 months: MD 7.51 95% CI 0.63-14.40, \( P < 0.05 \)). There is no statistically difference of AFS, major amputation, dissection, embolization and bailout stent between CELA group and PTA group (MD −2.82, 95% CI −8.86-3.22, \( P = 0.36 \); MD −0.17, 95% CI −1.04-0.70, \( P = 0.39 \); MD 1.11, 95% CI 0.58-2.10, \( P = 0.75 \); MD 0.46, 95% CI 0.11-1.99, \( P = 0.30 \); MD 1.89, 95% CI 0.92-3.88, \( P = 0.09 \)).

Conclusions: CELA had superior clinical (freedom from TLR) and angiographic outcomes (patency rate) for infrapopliteal arterial occlusion at the same time CELA does...
not have increased intervention-related complications compared to PTA. However, CELA is unable to improve the patient’s limb salvage rate compared with PTA.

**Keywords:** cool excimer laser-assisted angioplasty, percutaneous transluminal angioplasty, infrapopliteal arterial occlusion, peripheral arterial disease, endovascular intervention

**INTRODUCTION**

Infrapopliteal peripheral arterial disease (PAD) has a high rate of limb loss within 6 months when untreated (1, 2). The overall morbidity of PAD is in the range of 3-10%, and increases to 15-20% in persons over 70 years. With the trend of the aging, the social and economic burden of PAD is considerable. Endovascular intervention, such as angioplasty, debulking, and stenting offer a less invasive method, but evidence of safety and efficacy is heterogenous (3). Infrapopliteal arterial disease is often accompanied by extensive severe calcification, lumen narrowing, and poor distal outflow tracts, significantly increasing the difficulty of endovascular therapy and resulting in high likelihood of restenosis and the need of revascularization.

Recent reports have indicated considerable results of angioplasty for the treatment of infrapopliteal artery occlusion and benefited equivalent clinical limb salvage rates to bypass surgery (4). However, plain of balloon angioplasty (POBA) has a high rate of reocclusion, revascularization and complications (embolization, dissection, bailout stenting). Theoretically, excimer laser removes biologic tissue by photochemical desorption and the injected energy would convert the tissue to vaporized fragments (5). Cool excimer laser-assisted angioplasty (CELA) can decrease the rate of residual stenosis, thromboembolization, perforation to some extent (6). Traditionally, underdeveloped application of laser resulted in poor immediate and mid-term outcomes (7, 8), while recent studies have reported satisfactory clinical outcomes in high-volume centers with refinement of laser techniques (1, 9). However, clinical efficacy of CELA for infrapopliteal arterial occlusion is inconclusive.

We aim to determine the safety and efficacy of CELA for infrapopliteal arterial occlusion by carried out this meta-analysis of prospective and retrospective cohort studies and randomized controlled trials.

**MATERIALS AND METHODS**

Our study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for meta-analysis (Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement).

**Search Strategy and Inclusion Criteria**

All relevant studies published until April 2021 were searched in PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) without language restrictions. The following subject headings and keywords: “Laser” OR “laser angioplasty” OR “laser angioplasties” OR “angioplasties” OR “repair, endoluminal” OR “infrapopliteal” and “popliteal” OR “infragenicular” OR “percutaneous transluminal angioplasty” OR “transluminal angioplasty” and “percutaneous transluminal angioplasty” OR “endoluminal repair” et al. We contacted the corresponding author of the article to obtain related information not available from the dataset.

**Inclusion and Exclusion Criteria**

Inclusion criteria were (1) prospective and retrospective cohort studies and randomized controlled trials; (2) patients with infrapopliteal occlusion; (3) treatment methods were CELA or PTA; (4) a minimum follow-up of 6 months.

**Endpoints and Data Extraction**

The primary study endpoints refer to the endpoints that are directly related to the main purpose of the clinical therapy and provide the most clinically meaningful and convincing evidence. The secondary study endpoints are supportive of the primary endpoints. The secondary endpoints can be considered as an auxiliary support for the benefit of patients when the primary endpoints cannot be completed due to a long observation time.

The primary study endpoints were primary patency (6 months and 12 months), free from TLR (3 years) and amputation-free survival (AFS). The secondary endpoints included the major amputation (1 year), bailout stenting, dissection, embolization.
### TABLE 1 | Characteristics of included trials.

| References                  | Design                  | Hypertension | DM | CAD | Dyslipidemia | Age, y | n   | Male gender | ABI   | TASC class |
|-----------------------------|-------------------------|--------------|----|-----|--------------|--------|-----|-------------|-------|------------|
| Sultan et al. (6)           | Single center, prospective, controlled | CELA         | 26 (62%) | 32 (77%) | 15 (37%) | 68 (52–86) | 42 | 22 (52%) | 0.35 | B = 5 (11.9%); C = 13 (30.9%); D = 18 (42.8%) |
| PTA                        | CELA                    | 32 (69%)     | 38 (82%) | 16 (34%) | 36 (77%) | 70 (48–96) | 47 | 25 (53%) | 0.39 | B = 5 (10.6%); C = 13 (27.6%); D = 18 (38.3%) |
| Steinkamp et al. (10)       | Single center, prospective, nonrandomized, controlled | CELA         | 52 (40.9%) | 35 (27.5%) | 23 (18.1%) | 64.0 ± 9.7 (49–88) | 127 | 70 (55%) | 0.34 ± 0.16 | A/B = 99 (78%); C = 17 (13.4%); D = 11 (8.7%) |
| PTA                        | CELA                    | 42 (47.7%)   | 21 (23.8%) | 18 (20.4%) | 62.0 ± 8.7 (48–83) | 88 | 52 (59%) | 0.33 ± 0.18 | A/B = 74 (84.1%); C = 10 (11.4%); D = 4 (4.5%) |
| Bories et al. (11)          | Dual-center, prospective, nonrandomized, controlled | CELA         | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 |
| PTA                        | CELA                    | 320 (97.6%)  | 188 (57.3%) | 223 (68%) | 314 (95.7%) | 71.14 ± 12.7 | 237 | 160 (67.5%) | 0.25 | TASC C/D = 53 (45%) |
| Kokkinidis et al. (12)      | Dual-center, retrospective, nonrandomized, controlled | CELA         | 66 (87%) | 49 (64%) | 33% (25/76) | 153.8 (51.1%) | 76 | 57 (75%) | 0.36 | TASC C/D = 47 (82%) |
| PTA                        | CELA                    | 204 (86%)    | 186 (78%) | 52% (122/234) | 135.9 (44.3%) | 70.1 ± 12.7 | 237 | 160 (67.5%) | 0.25 | TASC C/D = 53 (45%) |
| Singh et al. (13)           | Single-center, retrospective, nonrandomized, controlled | CELA         | 374 (96.1%) | 232 (59.8%) | 70.7% (275/398) | 370 (95.1%) | 398 | 213 (53.5%) | 0.25 | TASC C/D = 53 (45%) |
| PTA                        | CELA                    | 322 (97.6%)  | 190 (57.6%) | 67.9% (224/333) | 316 (95.8%) | 71.1 ± 11.8 | 333 | 183 (55 %) | 0.25 | A/B = 0; C = 111 (33.3%); D = 222 (66.7%) |

DM, Diabetes mellitus; CAD, Coronary heart disease; ABI, Ankle brachial index; TASC class, Trans-Atlantic Inter-Society Consensus committee class.
Data were extracted from each selected study: name of the first author, study design, patient characteristics (basic disease, age, number of patients and sex ratio, ABI, TASC class). The details are shown in Figure 1. Data search and extraction, risk of bias was performed by two reviewers independently in accordance with the PRISMA recommendations. We assessed the risk of bias of prospective and retrospective studies according to Effective Practice and Organization of Care (EPOC) criteria.

### Data Synthesis and Statistical Analysis

Mean difference (MD) with 95% confidence intervals (CIs) and Odds ratio (OR) with 95% CIs were used to summarize the continuous and dichotomous variables, respectively. We used the Cochran's Q-statistic test and the I² test to assess the heterogeneity between studies, with I² more than 50% and p < 0.05 suggesting significantly heterogeneity, a random-effects model was adopted. Otherwise, we adopted a fixed effects model to evaluate the overall effect. Subgroup analysis were performed based on the following factors: publication year, region and samples size. Sensitivity analysis was performed through studies exclusion one by one. Review Manager Version (version 5.4; Cochrane Collaboration, Copenhagen, Denmark) was used to perform statistical analysis.

### RESULTS

#### Study Selection

Initially, 122 articles were obtained by searching with the proposed input, and 116 articles were retrieved after removing duplicates. 93 articles were initially excluded after reading the titles and abstracts because they did not meet the inclusion criteria or met the exclusion criteria. A total of 23 articles was investigated, and 17 of them were excluded by reading full-text. Finally, 6 articles were included in the meta-analysis (3, 6, 10–13).

Figure 1 shows the process of literature search in detail.

#### Study Characteristics

A total 6 studies with 2,217 participants were included in meta-analysis. Most of the included patients suffer from hypertension, diabetes, hyperlipidemia and coronary artery disease. More details of patients' clinical characteristics are showed in Table 1.

#### Risk of Bias and Quality Assessment

The risk-of-bias assessment of included prospective and retrospective studies was assessed according to the Cochrane Collaboration's tool and summarized in Figures 1, 2, respectively. The risk of bias on study outcomes is typically judged by the researchers according to an assessment of the quality of each individual study from the aspects of sampling bias, selection bias, and intra-study bias.

#### Primary Study Endpoints

**Patency**

Three studies reported the artery patency of target lesion at 6 months follow-up. The patency of CELA group was higher than the PTA group (MD 13.01, 95% CI 3.12-22.90, P = 0.01) using a random effects model (I² = 99%, P < 0.00001) (Figure 3).

Three studies reported the artery patency of target lesion at 1 year follow-up. The patency of CELA group was higher than the PTA group (MD 11.88, 95% CI 8.38-15.37, P < 0.00001) using a random effects model (I² = 99%, P < 0.00001) (Figure 4).

#### Freedom From TLR

Three studies reported freedom from TLR at 3 years follow-up. The rate of freedom from TLR in the CELA group was significantly higher than the PTA group (MD 7.51, 95% CI 0.63-14.40, P < 0.00001) using a random effects model (I² = 99%, P = 0.03) (Figure 5).

#### Amputation-Free Survival

Three studies reported amputation-free survival at 1 year follow-up. The rate of amputation-free survival was no statistical difference between CELA group and the PTA group (MD −2.82, 95% CI −8.86-3.22, P < 0.00001) using a random effects model (I² = 98%, P = 0.36) (Figure 6).

#### The Secondary Study Endpoints

**Major Amputation**

Four studies reported major amputation at 1 year follow-up. The rate of major amputation was no statistical difference between
Zhou et al. CELA vs. PTA in PAD

FIGURE 3 | Forest plot for 6-month patency. Random, a randomized effects model; CI, confidence intervals. The green squares stand for the weight of studies in meta-analysis. Black rhomboid represents the effects of combination of above three studies.

FIGURE 4 | Forest plot for 1-year patency. Random, a randomized effects model; CI, confidence intervals. The green squares stand for the weight of studies in meta-analysis. Black rhomboid represents the effects of combination of above three studies.

FIGURE 5 | Forest plot for freedom from TLR at 3 years. Random, a randomized effects model; CI, confidence intervals; TLR, target lesion revascularization. The green squares stand for the weight of studies in meta-analysis. Black rhomboid represents the effects of combination of above three studies.

FIGURE 6 | Forest plot for amputation-free survival (AFS). Random, a randomized effects model; CI, confidence intervals. The green squares stand for the weight of studies in meta-analysis. Black rhomboid represents the effects of combination of above three studies.

CELA group and the PTA group (MD $-0.17$, 95% CI $-1.04$ to $0.70$, $P < 0.00001$) using a random effects model ($I^2 = 100\%$, $P = 0.70$) (Figure 7).

Bailout Stenting
Two studies reported bailout stenting during the process of surgery. The rate of bailout stenting was no statistical difference between CELA group and the PTA group (OR 1.89, 95% CI 0.92-3.88, $P = 0.88$) using a fixed effects model ($I^2 = 0\%$, $P = 0.09$) (Figure 8).

Dissection
Five studies reported vessel dissection during the process of surgery. The rate of dissection was no statistical difference
between CELA group and the PTA group (OR 1.11, 95% CI 0.58-2.10, \( P = 0.0001 \)) using a random effects model (\( I^2 = 83\% \), \( P = 0.75 \)) (Figure 9).

**Embolization**

Four studies reported ectopic embolization during the process of surgery. The rate of vessel embolization was no statistical difference between CELA group and the PTA group (OR 0.46, 95% CI 0.11-1.99, \( P = 0.01 \)) using a random effects model (\( I^2 = 72\% \), \( P = 0.30 \)) (Figure 10).

**DISCUSSION**

Our meta-analysis evaluated the efficiency and safety of CELA therapy vs. PTA alone for treatment of patients suffering infrapopliteal artery occlusion disease for the first time. Comparing with conventional PTA alone, CELA therapy showed a significantly higher patency of 6 months and 1 year in target lesion, offered the advantages of an increase rate free from TLR, meanwhile not increased surgery complication (embolization, bailout stenting, dissection). However, CELA could not reduce major amputation and amputation-free survival. These data provide evidence that CELA maybe a more effective and safer therapeutic strategy for infrapopliteal artery occlusion.

Laser-assist angioplasty was firstly applied for vascular intervention since the early 1980s in coronary disease (14). Initially, underdevelopment use of the laser resulted in high rate of complications (perforation, dissection, and thermal injury) (15, 16). With the advance of equipment and technology, recent studies have reported some convincing result supporting laser for the treatment of peripheral artery disease. There have many meta-analyses compare the efficacy and safety between laser-assist angioplasty and POBA in iliofemoral artery occlusion, however, no meta-analysis summarized laser effectiveness on infrapopliteal artery occlusion. Our finding verified showed that CELA therapy shows superior clinical outcome over POBA.

The importance of infrapopliteal artery patency upon clinical outcomes was recently reported by some studies (17–20). Tibial arterial patency was mandatory during the process of wound healing (4, 21, 22). Baumann F observed a prolong time of wound healing in tibial restenosis patients and a significant corroboration with TLR and POBA (20). Target lesion revascularization was necessary in 48% of patients with restenosis of the tibial artery in 73% at 12-month follow-up. Restenosis was observed in 68.8 and 74% of limbs in CLI patients undergoing tibial artery POBA after 3 months and 1 year, respectively (23, 24). In our analysis, three studies recorded the patency of target vessel during 6-month and 12-month follow-up and 3-year freedom from TLR verified that CELA has a higher patency rate and free from TLR over POBA alone. This may be due to the excimer laser can selectively ablate atherosclerotic plaques and thrombi, while reducing subintimal angioplasty (25, 26). Our findings are in accordance with the results of the study of Laird et al. that CELA can be used for complex anatomic lesions with a high technical success and admirable short-term success rates (27).

However, our finding also verified that there is no advantage of AFS and major amputation rate to CELA compared with POBA.
alone. Higher patency of infrapopliteal artery did not translate into high limb salvage rate. This is very similar to other studies' conclusion. Michael C represented this result as a case-selection bias, accounting that CELA was not usually used on cases where a guidewire could not be successfully access to the occlusion lesion and suggested a randomized trial to verify the result (28). Our findings are in accordance with the results of the study of Romiti et al. that significant differences in patency rate did not result in significant difference in clinical outcomes (limb salvage) (4). Based on these findings, we assumed that the increased perfusion to the target lesion was mandatory to wound healing but not for keeping tissue integrity.

Theoretically, the excimer laser can vaporize intravascular plaques, effectively remove hyperplastic tissue (29), thereby reducing the risk of ectopic embolism. Laser atherectomy can reduce the probability of dissection after PTA, the implantation of bail-out stents and avoidance of subintimal technique. Previous studies reported embolism after PTA occurred in 2.6% of the cases (30) and laser atherectomy related distal embolization occurred in 3-10% of the cases (27, 31–35). However, our findings suggested that there is no significant advantage to CELA compare to POBA in surgery complications (dissection, embolization, bail-out stenting). We represented the result as case-selection bias. Patients with CELA therapy have more probabilities to accompany by severe calcifications. Calcification lesions are related to the dissection post-PTA, ectopic embolization and bailout stents, resulting in the finding that CELA has no obvious advantage in surgical complications compared with POBA. Without a randomized clinical trial, this result is difficult to address, but admittedly the datasets are not positive.

Limitations of our analysis included the retrospective studies other than Randomized Controlled Trial (RCT) trial and relatively small samples size. Retrospective nature could lead to various biases, resulting more determinants for outcome, however, currently there is no RCT study on laser treatment of the infrapopliteal artery. The relatively small samples size magnifies the result of analysis process. The current evidence is not sufficient to represent a real-world application of CELA technology for infrapopliteal artery occlusion revascularization, however, our findings tend to mirror contemporary revascularization studies.

CONCLUSION

Our meta-analysis showed that CELA has superior patency rate (6 months and 12 months) and freedom from TLR. However, comparing to POBA therapy, CELA did not decrease amputation rate and AFS, meanwhile had no advantage in surgery complications. Considering the retrospective nature of our analysis and inherent bias shortcomings, there is no any indication for revascularization. Large-scale RCTs are needed to verify...
the safety and efficiency of CELA therapy to infrapopliteal artery occlusion.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

MZ and YG designed the methods, analyzed the data, and results. MZ and LQ wrote the manuscript and prepared figures.

REFERENCES

1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. (2006) 113:e463–e654. doi: 10.1161/CIRCULATIONAHA.106.174526

2. Elsayed S, Clavijo LC. Critical limb ischemia. Cardirol Clin. (2015) 33:37–47. doi: 10.1016/ccl.2014.09.008

3. Piyaskulkaew C, Parvataneni K, Ballout H, Szpunar S, Sharma T, Almamoud M, et al. Laser in infrapopliteal and popliteal stenosis 2 study (LIPS2): long-term outcomes of laser-assisted balloon angioplasty versus balloon angioplasty for below knee peripheral arterial disease. Catheter Cardiovasc Interv. (2015) 86:1211–8. doi: 10.1002/ccd.26145

4. Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. (2008) 47:975–81. doi: 10.1016/j.vjs.2008.01.005

5. Grundfest WS, Litvack F, Forrester JS, Goldenberg T, Swan HJ, et al. Laser ablation of human atherosclerotic plaque without adjacent tissue injury. J Am Coll Cardiol. (1985) 5:929–33. doi: 10.1016/S0735-1097(85)80435-6

6. Sultan S, Tawfick W, Hynes N. Cool excimer laser-assisted angioplasty (CELA) and tibial balloon angioplasty (TBA) in management of infragenicular arterial occlusion in critical lower limb ischemia (CLI). Vasc Endovascular Surg. (2013) 47:179–91. doi: 10.1177/1538574413478473

7. Visona A, Perisinotto C, Lusiani L, Bonanome A, Pesavento R, Miserocchi L, et al. Percutaneous excimer laser angioplasty of lower limb vessels results of a prospective 24-month follow-up. Angiology. (1998) 49:91–8. doi: 10.1177/000331997804900201

8. Pokrovsky AV, Volynsky Ju D, Konov VL, Sargin ME, Silenok AS, Goloma VV, et al. Recanalisation of occluded peripheral arteries by excimer laser. Eur J Vasc Surg. (1990) 4:575–81. doi: 10.1016/0955-882X(90)80810-2

9. Second European Consensus Document on chronic critical leg ischemia. Eur J Vasc Surg. (1992) 6(Suppl A): 1–32.

10. Steinkamp HJ, Rademaker J, Wissgott C, Scheinert D, Werk M, Settmacher U, et al. Percutaneous transluminal laser angioplasty versus balloon dilation for treatment of popliteal artery occlusion. J Endovasc Ther. (2002) 9:882–8. doi: 10.1177/152660280200900623

11. Bosiers M, Hart JP, Deloose K, Verbit J, Peeters P. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. Vascular. (2006) 14:63–9. doi: 10.2310/6670.2006.00014

12. Kokkinidis DG, Giannopoulos S, Jawaid O, Cantu D, Singh GD, Armstrong EJ. Laser atherectomy for infrapopliteal lesions in patients with critical limb ischemia. Cardiovasc Revasc Med. (2021) 23:79–83. doi: 10.1016/j.carrev.2020.08.041

13. Singh T, Kodenchery M, Artham S, Piyaskulkaew C, Szpunar S, Parvataneni K, et al. Laser in infra-popliteal and popliteal stenosis (LIPS): retrospective review of laser-assisted balloon angioplasty versus balloon angioplasty alone for below knee peripheral arterial disease. Cardiovasc Interv Ther. (2014) 29:109–16. doi: 10.1007/s12928-013-0217-5

14. Das TS. Percutaneous peripheral revascularisation with excimer laser: equipment, technique and results. Lasers Med Sci. (2001) 16:101–7. doi: 10.1007/PL00011338

15. Bonn D. Laser thrombolysis: safe and rapid removal of clots? Lancet. (2000) 355:1976. doi: 10.1016/S0140-6736(05)72916-0

16. Gallino A, Mahler F, Probst P, Nachbur B. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation. (1984) 70:619–23. doi: 10.1161/01.CIR.70.4.619

17. Liistro F, Porto I, Angioli P, Grotti S, Ricci L,ucci K, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. (2013) 128:615–21. doi: 10.1161/CIRCULATIONAHA.113.008111

18. Rastan A, Brechtel K, Krankenberg H, Zahorsky R, Tepe G, Noory E, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. (2012) 60:587–91. doi: 10.1016/j.jacc.2012.04.035

19. Iida O, Soga Y, Kawasaki D, Hirano K, Yamaoka T, Suzuki K, et al. Angiographic restenosis and its clinical impact after infrapopliteal angioplasty. Eur J Vasc Endovasc Surg. (2012) 44:425–31. doi: 10.1016/j.ejvs.2012.07.017

20. Baumann F, Bloesch S, Engelberger RP, Makaloski V, Fink H, Do DD, et al. Clinically-driven need for secondary interventions after endovascular revascularization of tibial arteries in patients with critical limb ischemia. J Endovasc Ther. (2013) 20:707–13. doi: 10.18533/143755M1

21. Paglia E, Clerici G, Clerissi J, Gabrielli L, Laos S, Mantero M, et al. Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: data of a cohort study of 564 patients. Eur J Vasc Endovasc Surg. (2006) 32:484–90. doi: 10.1016/j.ejvs.2006.03.006

22. Ferrari R, Centola M, Ferlini M, Da Ros R, Caravaggi C, Assaloni R, et al. Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia. Eur J Vasc Endovasc Surg. (2009) 37:336–42. doi: 10.1016/j.ejvs.2008.12.001

All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGMENTS

We would like to thank all the clinical and research staff who made it possible to perform this study.

FUNDING

This study was supported by the National Key Research and Development Program of China (No. 2017YFC1104100).

Zhou et al. CELA vs. PTA in PAD
extensive infrapopliteal arterial disease. *Catheter Cardiovasc Inter*. (2010) 76:1047–54 doi: 10.1002/ccd.22658

24. Baumann F, Özdoğa C, Grochenig E, Diehm N. The Importance of patency in patients with critical limb ischemia undergoing endovascular revascularization for infrapopliteal arterial disease. *Front Cardiovasc Med*. (2014) 1:17. doi: 10.3389/fcvm.2014.00017

25. Strebel RT, Utzinger U, Peltola M, Schneider J, Niederer PF, Hess OM. Excimer laser spectroscopy: influence of tissue ablation on vessel wall fluorescence. *J Laser Appl*. (1998) 10:34–40. doi: 10.2351/1.521831

26. Dahm JB, Ruppert J, Doerr M, Bordihn N, Maybauer W. Percutaneous laser-facilitated thrombectomy: an innovative, easily applied, and effective therapeutic option for recanalization of acute and subacute thrombotic hemodialysis shunt occlusions. *J Endovasc Ther*. (2006) 13:603–8. doi: 10.1583/06-1829MR.1

27. Laird JR, Zeller T, Gray BH, Scheinert D, Vranic M, Reiser C, et al. Investigators. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. *J Endovasc Ther*. (2006) 13:1–11. doi: 10.1583/05-1674.1

28. Stoner MC, deFreitas DJ, Phade SV, Parker FM, Bogey WM, Powell S. Mid-term results with laser atherectomy in the treatment of infrainguinal occlusive disease. *J Vasc Surg*. (2007) 46:289–95. doi: 10.1016/j.jvs.2007.04.019

29. Mehran R, Mintz GS, Satler LF, Pichard AD, Kent KM, Bucher TA, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. *Circulation*. (1997) 96:2183–9. doi: 10.1161/01.CIR.96.7.2183

30. Yoshino K, Terai Y, Fujimoto S, Kamata I, Kinugasa K, Nishimoto A. The reconstructions for vertebral artery stenosis at the origin. a comparison between PTA and surgical reconstructions. *Interv Neuroradiol*. (2000) 6(Suppl 1):237–42. doi: 10.1177/15910199000060S140

31. Dippel EJ, Makam P, Kovach R, George JC, Patirola R, Metzger DC, et al. Investigators. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCimer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis). *JACC Cardiovasc Inter*. (2015) 8:92–101. doi: 10.1016/j.jcin.2014.09.009

32. McKinsey JF; Zeller T, Rocha-Singh KJ, Jaff MR, Garcia LA, Investigators DL. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. *JACC Cardiovasc Inter*. (2017) 9:723–33. doi: 10.1016/j.jcin.2014.05.006

33. Zeller T, Krankenberg H, Steinkamp H, Rastan A, Sixt S, Schmidt A, et al. One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial. *J Endovasc Ther*. (2009) 16:653–62. doi: 10.1583/09-2826.1

34. Schmidt A, Zeller T, Sievert H, Krankenberg H, Torsello G, Stark MA, et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. *J Endovasc Ther*. (2014) 21:52–60. doi: 10.1583/13-4538R.1

35. Shrikhande GV, Khan SZ, Hussain HG, Dayal R, McKinsey JF; Morrissey N. Lesion types and device characteristics that predict distal embolization during percutaneous lower extremity interventions. *J Vasc Surg*. (2011) 53:547–52. doi: 10.1016/j.jvs.2010.09.008

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Zhou, Qi and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**